表紙
市場調査レポート

Treventis Corporation - 製品パイプライン分析

Treventis Corporation - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 311251
出版日 ページ情報 英文 22 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
Treventis Corporation - 製品パイプライン分析 Treventis Corporation - Product Pipeline Review - 2014
出版日: 2014年08月25日 ページ情報: 英文 22 Pages
概要

Treventis Corporation は、アルツハイマー病やパーキンソン病、ハンチントン病などの様な、タンパク質の誤った畳み方に起因する疾患治療のための薬の研究開発に取り組むバイオテクノロジー企業です。同社独自の特許出願中である、集合体コンピュータモデル、「共通立体配座モチーフ」は、ベータアミロイド集合体の分子機構に特化したものです。

当レポートでは、Treventis Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Treventis Corporationの基本情報

Treventis Corporationの概要

  • 主要情報
  • 企業情報

Treventis Corporation:R&Dの概要

  • 主な治療範囲

Treventis Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Treventis Corporation:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Treventis Corporation:薬剤プロファイル

  • TRV-1140
  • TRV-1387
  • TRV-217
  • Small Molecule for Huntingtons Disease
  • Small Molecule for Parkinsons Disease

Treventis Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Treventis Corporation:本社と子会社の所在地

付録

図表一覧

目次
Product Code: GMDHC06111CDB

Summary

Global Markets Direct's, 'Treventis Corporation - Product Pipeline Review - 2014', provides an overview of the Treventis Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Treventis Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Treventis Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Treventis Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Treventis Corporation's pipeline products

Reasons to buy

  • Evaluate Treventis Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Treventis Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Treventis Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Treventis Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Treventis Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Treventis Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Treventis Corporation Snapshot
    • Treventis Corporation Overview
    • Key Information
    • Key Facts
  • Treventis Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Treventis Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Treventis Corporation - Pipeline Products Glance
    • Treventis Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Treventis Corporation - Drug Profiles
    • TRV-1140
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRV-1387
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRV-217
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Huntingtons Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Parkinsons Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Treventis Corporation - Pipeline Analysis
    • Treventis Corporation - Pipeline Products by Target
    • Treventis Corporation - Pipeline Products by Route of Administration
    • Treventis Corporation - Pipeline Products by Molecule Type
    • Treventis Corporation - Pipeline Products by Mechanism of Action
  • Treventis Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Treventis Corporation, Key Information
  • Treventis Corporation, Key Facts
  • Treventis Corporation - Pipeline by Indication, 2014
  • Treventis Corporation - Pipeline by Stage of Development, 2014
  • Treventis Corporation - Monotherapy Products in Pipeline, 2014
  • Treventis Corporation - Preclinical, 2014
  • Treventis Corporation - Discovery, 2014
  • Treventis Corporation - Pipeline by Target, 2014
  • Treventis Corporation - Pipeline by Route of Administration, 2014
  • Treventis Corporation - Pipeline by Molecule Type, 2014
  • Treventis Corporation - Pipeline Products by Mechanism of Action, 2014
  • Treventis Corporation, Other Locations

List of Figures

  • Treventis Corporation - Pipeline by Top 10 Indication, 2014
  • Treventis Corporation - Pipeline by Stage of Development, 2014
  • Treventis Corporation - Monotherapy Products in Pipeline, 2014
  • Treventis Corporation - Pipeline by Top 10 Target, 2014
  • Treventis Corporation - Pipeline by Top 10 Molecule Type, 2014
  • Treventis Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top